Isfahan University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Dapagliflozin in Patients With Chronic Kidney Disease: A Systematic Review and Meta-Analysis on Randomized, Double-Blind, Placebo-Controlled Multicenter Trials Publisher



Khodabandeh H1 ; Molaee H2 ; Ghashghaie L3 ; Farnia MR4 ; Alivand S5 ; Zandiyeh F6 ; Gharebakhshi F1 ; Rashidi E7 ; Mir N8
Authors
Show Affiliations
Authors Affiliations
  1. 1. Department of Radiology, Imam Hossein Hospital, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran
  2. 2. Department of Nursing, Faculty of Nursing and Midwifery, Shahid Beheshti University of Medical Sciences, Tehran, Iran
  3. 3. Department of Anesthesiology, Student Research Committee, Faculty of Nursing and Midwifery, Hormozgan University of Medical Sciences, Bandar Abbas, Iran
  4. 4. Department of Emergency Medicine, Taleghani and Imam Reza Hospitals, School of Medicine, Kermanshah University of Medical Science, Kermanshah, Iran
  5. 5. Department of Biostatistical and Epidemiology, School of Health, Isfahan University of Medical Sciences, Isfahan, Iran
  6. 6. Department of Emergency Medicine, Shohadaye Salamat Hospital, Iran University of Medical Sciences, Tehran, Iran
  7. 7. Department of Critical Care, Razi School of Nursing and Midwifery, Kerman University of Medical Sciences, Kerman, Iran
  8. 8. Department of Nursing, Khatam al Anbia Hospital, Faculty of Nursing and Midwifery, Iranshahr University of Medical Sciences, Iranshahr, Iran

Source: Journal of Nephropathology Published:2025


Abstract

Introduction: Sodium-glucose cotransporter-2 (SGLT2) inhibitors reduce the mortality rate, hospitalization, and cardiac morbidity in diabetic patients. However, their safety in chronic kidney disease (CKD) individuals is still debatable. Objectives: The present study aims to evaluate the effect of dapagliflozin on primary composite outcomes and mortality rate in CKD patients using a systematic review and meta-analysis approach. Materials and Methods: In this meta-analysis, Cochrane, Web of Science, Scopus, and PubMed databases, along with the Google Scholar search engine, were queried until March 2023. Data were analyzed by STATA software version 14 at a significance level of P < 0.05. Results: A total of nine randomized clinical trials (RCTs) articles were reviewed, with a sample size of 16720 in the dapagliflozin group and 13 476 in the placebo group. Dapagliflozin use (10 mg/d) compared to placebo improved primary composite outcomes in CKD patients by 39% (OR=0.61, 95% CI: 0.57, 0.65) while reducing the mortality rate by 31% (OR=0.69, 95% CI: 0.63, 0.76). In an analysis by treatment length, no statistically significant change was noted in early composite outcomes (OR=0.70, 95% CI: 0.48, 1.01) and mortality rate (OR=0.75, 95% CI: 0.39, 1.45) between patients who were on dapagliflozin for less than two years and the placebo group. However, patients receiving dapagliflozin for two years and above had significantly improved primary composite outcomes (OR=0.60, 95% CI: 0.55, 0.66) and mortality rate (OR=0.69, 95% CI: 0.61, 0.79) compared to the placebo group. Conclusion: Dapagliflozin use, compared to placebo, improved the early composite outcomes and mortality rate in CKD patients. Prescribing a daily dose of 10 mg for a treatment duration of over two years seems safe in these patients. © 2025 The Author(s).
7. Metformin Induced Acute Kidney Injury; a Systematic Review, Journal of Nephropharmacology (2021)
Experts (# of related papers)
Other Related Docs
11. D-Dimer Levels in Chronic Kidney Illness: A Comprehensive and Systematic Literature Review, Proceedings of the National Academy of Sciences India Section B - Biological Sciences (2020)
12. Diabetes Mellitus and Renal Failure: Prevention and Management, Journal of Research in Medical Sciences (2015)
28. Salsalate Efficacy in Blood Glucose Level Reduction in Diabetes, Journal of Isfahan Medical School (2009)
30. Comparison of the Performance of the Updated Schwartz, Combined Schwartz and the Grubb Glomerular Filtration Rate Equations in a General Pediatric Population., Saudi journal of kidney diseases and transplantation : an official publication of the Saudi Center for Organ Transplantation, Saudi Arabia (2014)
31. Dapagliflozin: An Effective Adjunctive Treatment in Type 1 Diabetes, Cardiovascular Endocrinology and Metabolism (2021)
42. Antihypertensive Drug Prescription Trends in Shahrekord, Iran, Journal of Nephropharmacology (2022)
47. Renoprotective Effects of Metformin, DARU, Journal of Pharmaceutical Sciences (2013)